==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1087 which contains 2 entries.


Entry 1
(1) Primary information
ID1460
ThPP IDTh1087
Therapeutic Peptide/Protein NameOxytocin
SequenceCYIQNCPLG view full sequnce in fasta
Functional ClassificationIb
Molecular Weight1007.187
Chemical FormulaC43H66N12O12S2
Isoelectric Point5.51
Hydrophobicity-2.7
Melting Point (℃)N.A.
Half Life1-6 min
Description9-residue cyclic peptide, synthetically prepared to avert possible contamination with vasopressin and small polypeptides
Indication/DiseaseTo assist in labor, elective labor induction, uterine contraction induction
PharmacodynamicsUsed to induce labor or to enhance uterine contractions during labor. Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+-dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca2+, which in turn activates myosins light chain kinase.. Oxytocin has specific receptors in the muscle llining of the uterus and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term.
Mechanism of ActionBinds the oxytocin receptor which leads to an increase in intracellular calcium levels. The oxytocin-oxytocin receptor system plays an important role as an inducer of uterine contractions during parturition and of milk ejection.
ToxicityN.A.
Metabolismhepatic oxytocinases
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesOxytocics, Anti-tocolytic Agents and Labor Induction Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetGlobotriaosylceramide
Information of corresponding available drug in the market
Brand NamePitocin
CompanyJHP Pharmaceuticals
Brand DiscriptionPitocin (oxytocin injection, USP) is a sterile, clear, colorless aqueous solution of synthetic oxytocin, for Intravenous infusion or intramuscular injection. Pitocin is a nonapeptide found in pituitary extracts from mammals. It is standardized to contain 10 units of oxytocic hormone/mL and contains 0.5% Chlorobutanol, a chloroform derivative as a preservative, with the pH adjusted with acetic acid. Pitocin may contain up to 16% of total impurities. The hormone is prepared synthetically to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity.
Prescribed forInduction or Stimulation of Labor, Control of Postpartum Uterine Bleeding, Treatment of Incomplete, Inevitable, or Elective Abortion
Chemical NameN.A.
FormulationN.A.
Physcial AppearancePitocin (oxytocin injection, USP) is a sterile, clear, colorless aqueous solution of synthetic oxytocin, for Intravenous infusion or intramuscular injection. Pitocin is a nonapeptide found in pituitary extracts from mammals. It is standardized to contain 10 units of oxytocic hormone/mL and contains
Route of AdministrationIntravenous infusion
Recommended Dosageinitial dose should be 0.5–1 mU/min (equal to 3–6 mL of the dilute oxytocin solution per hour). At 30–60 minute intervals the dose should be gradually increased in increments of 1–2 mU/min until the desired contraction pattern has been established.
ContraindicationDo NOT use Pitocin if: you are allergic to any ingredient in Pitocin; your birth canal is too small compared with the fetus's head; you have other complications that require medical intervention for birth; you have bacteria in the blood; you cannot have a child through vaginal delivery because of certain conditions (eg, genital herpes, cervical cancer)
Side EffectsSymptoms of overdose: Restlessness, shakiness, sleepiness, slow to respond, slurred speech, unconsciousness.
Useful Linkhttp://www.drugs.com/cdi/pitocin.html http://www.rxlist.com/pitocin-drug/indications-dosage.htm
PubMed ID14647484, 25637830, 25637811, 25637390, 25631363, 25628581, 25627343
3-D StructureTh1087 (View) or (Download)


Entry 2
(2) Primary information
ID1461
ThPP IDTh1087
Therapeutic Peptide/Protein NameOxytocin
SequenceCYIQNCPLG view full sequnce in fasta
Functional ClassificationIb
Molecular Weight1007.187
Chemical FormulaC43H66N12O12S2
Isoelectric Point5.51
Hydrophobicity-2.7
Melting Point (℃)N.A.
Half Life1-6 min
Description9-residue cyclic peptide, synthetically prepared to avert possible contamination with vasopressin and small polypeptides
Indication/DiseaseTo assist in labor, elective labor induction, uterine contraction induction
PharmacodynamicsUsed to induce labor or to enhance uterine contractions during labor. Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+-dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca2+, which in turn activates myosins light chain kinase.. Oxytocin has specific receptors in the muscle llining of the uterus and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term.
Mechanism of ActionBinds the oxytocin receptor which leads to an increase in intracellular calcium levels. The oxytocin-oxytocin receptor system plays an important role as an inducer of uterine contractions during parturition and of milk ejection.
ToxicityN.A.
Metabolismhepatic oxytocinases
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesOxytocics, Anti-tocolytic Agents and Labor Induction Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetInterferon alpha/beta receptor 2,Interferon alpha/beta receptor 1
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID14647484, 25637830, 25637811, 25637390, 25631363, 25628581, 25627343
3-D StructureTh1087 (View) or (Download)